Cantitate/Preț
Produs

The Living Brain and Alzheimer’s Disease: Research and Perspectives in Alzheimer's Disease

Editat de Bradley T. Hyman, Jean-Francois Demonet
en Limba Engleză Paperback – 15 apr 2014
From large cross-sectional studies of autopsy material, it seems as if a time course of Alzheimer's Disease, at least on average, can be mapped out: a pattern of hierarchical vulnerability for neuronal loss and neurofibrillary tangles beginning in medial temporal lobe structures proceeding through association areas. Plaques follow their own temporal course, with widespread cortical deposits occurring even early in a disease process. The whole process may well take twenty years, the first half of which may be without overt symptoms.
Citește tot Restrânge

Din seria Research and Perspectives in Alzheimer's Disease

Preț: 62294 lei

Preț vechi: 73288 lei
-15% Nou

Puncte Express: 934

Preț estimativ în valută:
11923 12508$ 9891£

Carte tipărită la comandă

Livrare economică 29 ianuarie-12 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783642639272
ISBN-10: 3642639275
Pagini: 200
Ilustrații: XV, 180 p. 50 illus., 33 illus. in color.
Dimensiuni: 155 x 235 x 11 mm
Greutate: 0.29 kg
Ediția:2004
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Research and Perspectives in Alzheimer's Disease

Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Research

Cuprins

Neuropathology of Alzheimer’s disease, as Seen in Fixed Tissues.- Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer’s Disease.- The Living Brain and Alzheimer’s Disease.- In Vivo Imaging of Alzheimer Pathology in Transgenic Mice Using Multiphoton Microscopy.- In Vivo Magnetic Resonance of Amyloid Plaques in Alzheimer’s Disease Model Mice.- Measuring Progression in Alzheimer’s Disease Using Sserial MRI: 4D MRI.- Validating MRI Measures of Disease Stage and Progression in Alzheimer’s Disease.- Dynamic Mapping of Alzheimer’s Disease.- Development of Benzothiazole Amyloid-Imaging Agents.- First PET Study with a Benzothiazol Amyloidimaging Agent (PIB) in Alzheimer’s Disease Patients and Hhealthy Volunteers.- Mild Cognitive Impairment (MCI): Predicting Conversion to Clinically Probable Alzheimer’s Disease with Fluoro-Deoxy-Glucose PET.- Positron Emission Tomography and Magnetic Resonance Imaging in the Study of Cognitively Normal Persons at Differential Genetic Risk for Alzheimer’s Dementia.

Textul de pe ultima copertă

How can we link the critical observations performed at autopsy with the events that occur over the previous twenty years of Alzheimer’s Disease? This is the problem posed to a group of our colleagues who are using state-of-the-art neural imaging methods in patients and in animal models to illuminate the natural history of the disease – in the living brain.